{
  "id": 20567542,
  "title": "Gilead signs generic licensing deals for experimental Ebola drug",
  "url": "https://urgent.news/2026/11/18/gilead-signs-generic-licensing-deals-for-experimental-ebola-drug",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-18T08:22:25.000Z",
  "source": {
    "name": "The Hindu Health",
    "slug": "the-hindu-health",
    "url": "https://www.thehindu.com/sci-tech/health/gilead-signs-generic-licensing-deals-for-experimental-ebola-drug/article71712679.ece"
  },
  "original_language": "en",
  "account": "Gilead Sciences recently announced agreements with three generic drug manufacturers to produce its experimental Ebola prevention drug, obeldesivir. This move aims to make the drug available in 127 low- and lower-middle-income countries, particularly those affected by the current Ebola Bundibugyo outbreak. The deals, which are royalty-free, include all African countries reporting Ebola cases. Obeldesivir has shown preclinical activity against several Ebola-related viruses but is not yet approved for any use. A late-stage trial is currently testing the drug in individuals at high risk of exposure. Gilead is also expanding remdesivir licenses, potentially covering Ebola-related diseases, if trial results and regulatory approvals prove positive. The company has donated over 38,000 vials of remdesivir to the Democratic Republic of Congo, Uganda, and Kenya, including a recent shipment to Kenya for investigational treatment and post-exposure prevention.",
  "summary": "A late-stage trial is testing the drug in people at high risk after exposure. The deals are intended to line up manufacturing and supply before trial results and regulatory filings",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Seeking Alpha News",
        "title": "Gilead grants voluntary licensing agreements for experimental Ebola antiviral",
        "url": "https://urgent.news/2026/11/16/gilead-grants-voluntary-licensing-agreements-for-experimental-ebola",
        "published": "2026-11-16T22:40:13.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}